Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

clinical investigation of the TLR7 mechanism in HCV by taking ANA773 into a clinical trial under a two-part protocol designed to test ANA773 in both healthy volunteers and patients with HCV. In October, Anadys completed dosing in healthy volunteers. Subjects received a single dose followed by four doses taken every other day, at levels from 200 mg to 1600 mg (with six subjects receiving active and two receiving placebo in each dose cohort). No serious adverse events were reported. Biomarker induction indicative of immune activation was seen in a majority of subjects beginning at 800 mg. Some side effects commonly seen with interferon treatment, including fever and chills, were observed at higher doses, with the frequency and intensity of interferon-like side effects increasing with dose. One subject at the 1200 mg dose and two subjects at the 1600 mg dose discontinued from the trial before completion of dosing. Anadys expects to initiate Part B of the study in HCV patients within the next few weeks. Patients in the first cohort will receive 800 mg of ANA773 every other day for 28 days. Doses for subsequent cohorts will be selected based on viral load and tolerability data from the 800 mg cohort.

-- Phase I Clinical Trial of ANA773 in Oncology. Anadys continues to enroll patients in an ongoing Phase I clinical trial of ANA773 in oncology and has now completed enrollment in the third cohort.

Webcast of Conference Call

Anadys will host a conference call at 5:00 p.m. EDT today to discuss its third quarter financial results and highlights and to provide an update on its development programs. A live webcast of the call will be available online at http://www.anadyspharma.com. A telephone replay will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 86226986. The webcast and t
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 2015 The Remedy Group , ... for the specialty pharmacy industry, will be exhibiting, presenting, ... Specialty Pharmacy Summit. The Summit will be held May ... and is the largest annual gathering for the specialty ... from pharmacy providers, pharma/biotech manufacturers, and payers, to learn ...
(Date:5/5/2015)... Calif. , May 5, 2015  23andMe, Inc., ... of the Lupus Research Study in collaboration ... individuals with systemic lupus erythematosus, more commonly known as ... genetics of lupus. The effort is also in collaboration ... Lupus Awareness Month in May. Approximately 1.5 ...
(Date:5/5/2015)... Israel , May 5, 2015  Tikcro ... Company was approved to continue trading on OTCQB  ... OTCQB Marketplace allows for a continuous ... broker-dealers. Investors can have real-time quotes and market ... The OTCQB Marketplace includes U.S. and ...
(Date:5/5/2015)... -- A group of biotechnology executives and medical doctors announced ... non-profit organization dedicated to providing education, research and therapeutic ... consciousness.  ... Coma is the ... actions can be initiated by the patient, and sleep-wake ...
Breaking Biology Technology:The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 4Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 5
... , ... DC Protein Assay reagents contain both detergent and base,which are required for cell lysis ... used for tissue cells; dry cells; protein precipitates from,heat, acid, or acetone treatment; or ... , , ...
... Slyker, B Gillece-Castro, M Nguyen, L Sapp, MG Brubacher, and WB , ... Association of Biomolecular Resource , Facilities (ABRF) , ... , Abstract , ... analysis. The quality and value of the information obtained from ...
... Roche Discovery Welwyn, 40 Broadwater Road, Welwyn , Garden ... Syngenta, Jealotts Hill International Research Centre, Bracknell, Berkshire, , ... Abstract , I ... running 2-D SDS-PAGE slab gels with preparative protein loads. The Dodeca ...
Cached Biology Technology:Total Cellular Protein Determination Using the DC Protein Assay 2Sample Preparation Solutions for Cellular Protein Fractionation Poster, Rev A 2Sample Preparation Solutions for Cellular Protein Fractionation Poster, Rev A 3Sample Preparation Solutions for Cellular Protein Fractionation Poster, Rev A 4Sample Preparation Solutions for Cellular Protein Fractionation Poster, Rev A 5Sample Preparation Solutions for Cellular Protein Fractionation Poster, Rev A 6Use of the PROTEAN Plus Dodeca Cell for Second-Dimension SDS-PAGE, Rev A 2Use of the PROTEAN Plus Dodeca Cell for Second-Dimension SDS-PAGE, Rev A 3Use of the PROTEAN Plus Dodeca Cell for Second-Dimension SDS-PAGE, Rev A 4Use of the PROTEAN Plus Dodeca Cell for Second-Dimension SDS-PAGE, Rev A 5
(Date:4/21/2015)... 2015 High crime rate, ... boosting access control systems market in Saudi ... recently published report by TechSci Research " Saudi Arabia Access ... control systems market in Saudi Arabia ... access control systems market in the Kingdom is growing ...
(Date:4/17/2015)... , April 17, 2015 ... security concerns, and technological advancement to drive biometric ... until 2020   According to ... Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market ... projected to register growth at CAGR of over ...
(Date:4/13/2015)... , April 13, 2015 ... TechSci Research, "Global Biometrics Market Forecast & Opportunities, 2020", ... a CAGR of around 14% till 2020. The ... for large scale implementation and review of biometric ... launch of new products with greater efficiency, are ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... meeting of the European Society of Human Reproduction and ... embryo) with an incorrect number of chromosomes (known as ... genetic normalisation" so that by day five, when it ... euploid, with the correct number of chromosomes. The ...
... calendar method predicted ovulation correctly in only one in ... test pack) predicted correctly in 99% of women over ... Scientific and Medical Affairs at SPD Swiss Precision Diagnostics ... it consisted of a digital reader and urine test ...
... the development of biofuels. In fact, it would appear they ... index and so ignite more easily. They also enhance its ... focused his research on the acetal known as 1.1 diethoxy ... obtaining it, and proposed alternative measures for the process to ...
Cached Biology News:Early embryos can correct genetic abnormalities during development 2Early embryos can correct genetic abnormalities during development 3Early embryos can correct genetic abnormalities during development 4Simple test gives accurate prediction of ovulation to help women become pregnant 2Processes for obtaining ecological compound that can optimize biodiesel enhanced 2Processes for obtaining ecological compound that can optimize biodiesel enhanced 3
ANTI END CEL LUNG AG...
For the quantitative determination of canine Interleukin 10,(IL-10) concentrations in cell culture supernates, canine serum,and plasma....
EGTA, 50 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
RAT ANTI RAT RT1Au (CLASS I POLYMORPHIC) Immunogen: AO lymphoid cells...
Biology Products: